Otros idiomas Revance Therapeutics, Inc.

Acciones

RVNC

US7613301099

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:01 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
3,95 ^USD	+4,77 %		+16,18 %	-55,06 %

26/04	AbbVie eleva su previsión anual de beneficios por las fuertes ventas de Skyrizi	RE
12/04	Revance Therapeutics, Inc. presentará nuevos datos sobre DAXXIFY en la reunión anual de la Academia Americana de Neurología 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Certain Restricted Stock Units of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	04/05/2024
Certain Common Stock of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	04/05/2024
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024	02/05
AbbVie raises annual profit forecast on strong Skyrizi sales	26/04
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	15/04
Northern District Of California Grants Motion To Dismiss Putative Class Action Against Biotech Company And Executives	15/04
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting	12/04
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	12/04
Revance Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	28/03
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	27/03
North American Morning Briefing: Stock Futures Fall With Investor Focus on Inflation Data	11/03
Court Finds Access To Botox Trade Secrets And Similarity Of Competitor Product Supported Inference Of Trade Secrets Misappropriation	07/03
Revance Therapeutics Prices $100 Million Public Offering	04/03
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock	04/03
Revance Announces Proposed Public Offering of Common Stock	04/03
Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q4 Revenue $69.8M	28/02
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update	28/02
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	28/02
Revance Therapeutics, Inc. Announces Executive Changes	28/02
Revance Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Revance Therapeutics, Inc.

Acciones

RVNC

US7613301099

Otros idiomas

Filtros